Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats

Abstract

Diabetic neuropathies are a family of nerve disorders caused by diabetes. Symptoms of the disease include nerve palsy, mononeuropathy, mononeuropathy multiplex, diabetic amyotrophy, painful polyneuropathy, autonomic neuropathy, and thoracoabdominal neuropathy. In this study, type 2 diabetes in rats was induced with nicotinamide-streptozotocin. Drug treatment was initiated on the d 15, with the combination regimen of metformin, pioglitazone and glimipiride or metformin and sitagliptin or sitagliptin, amitriptyline and sitagliptin and led to significantly improved glycemic control, increased grip strength and paw jumping response on d 21, 28 and 35 (P < 0.001). Significant increases in blood protein levels and decreases in urinary protein levels were observed in the animals treated with the different regimens on d 21, 28 and 35 (P < 0.001). Combined treatment of streptozotocin and nicotinamide caused marked degeneration of nerve cells, while administration of metformin and sitagliptin showed tissue regeneration and no body weight gain. In conclusion, treatment with sitagliptin and sitagliptin combined with metformin or amitriptyline results in no body weight gain, but causes an increase in grip strength and pain sensitivity, exhibits neural protection, and reverses the alteration of biochemical parameters in rats with streptozotocin-nicotinamide induced type 2 diabetes.

Hepato-renal protective effects of gallic acid and p-coumaric acid in nicotinamide/streptozotocin-induced diabetic rats

“…This could be due to dehydration, increase in muscle wasting (56) and catabolism of fats and proteins (57). These results run parallel with the studies of Pierre et al, (47) and Sharma et al, (58). Oral administration of gallic acid and p-coumaric acid to diabetic rats improved body weight and this could be due to a better control of hyperglycemic state in the diabetic rats.…”

Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats

“…Conversely, it is suggested that there are no differences in body weight between healthy and diabetic rats at the end of third week after birth [5]. It is reported that sitagliptin did not change the body weights of different species of diabetic animals [31,32]. By contrast with the previous studies, administration of sitagliptin regulated the body weight of diabetic rats in this study.…”

Drug combinations in diabetic neuropathic pain: an experimental validation

“…This precludes the possibility of its role in the treatment of diabetic neuropathic pain when administrated in acute doses. These results are consistent with a previous study that has reported increased pain sensitivity following sitagliptin administration for 35 days in STZ-nicotinamide-induced diabetic neuropathy in rats [42]. However, another study has reported that administration of sitagliptin for 48 weeks significantly reversed the decrease in tail-flick latencies in STZ-induced diabetic animals [43].…”